Patterns of Antiacids Use in Patients With IHD Admitted to Department of Internal Medicine
1 other identifier
observational
1,200
1 country
2
Brief Summary
There is substantial, continuing, and unexplained rise in prescribing of proton pump inhibitors. It is unknown whether their use in practice has corresponded to their licensed indications. Although the indications for H2RA or PPI administration in the treatment of acid-related diseases and the prevention of gastric mucosal damage have been well defined in the medical literature, the perception of benefit from their use frequently tends to be extrapolated to all patients in general, leading to an excessive consumption of these drugs in general practice. To date, however, little has been published with regard to the overall use or misuse of these drugs in hospital populations in ischemic heart disease patients as a secondary prevention to Aspirin use. We will undertake a 6-months retrospective survey (about 1200 patients) to evaluate the use of acid-suppressive medications in the general internal medicine ward of Rambam Hospital. We will extract all records of prescribing of a proton pump inhibitor within Rambam Hospital computerized patients file program (Premetheuos) in period of half year, categorized and analyze them using statistical X2 test.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2006
Shorter than P25 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2006
CompletedFirst Submitted
Initial submission to the registry
October 25, 2006
CompletedFirst Posted
Study publicly available on registry
October 26, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2006
CompletedApril 11, 2007
April 1, 2007
October 25, 2006
April 10, 2007
Conditions
Keywords
Eligibility Criteria
You may qualify if:
- Ischemic Heart Disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Rambam: Health Care Campus
Haifa, 31096, Israel
Rambam Health Care Campus
Haifa, Israel
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Zaher S Azzam, MD
Acting Director of Internal Medicine "B"
Study Design
- Study Type
- observational
- Observational Model
- DEFINED POPULATION
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
October 25, 2006
First Posted
October 26, 2006
Study Start
January 1, 2006
Study Completion
November 1, 2006
Last Updated
April 11, 2007
Record last verified: 2007-04